| Vol. 9.04 – 3 February, 2023 |
| |
|
|
| By whole-genome sequencing of 342 microdissected normal epithelial crypts from the small intestines of 39 individuals, investigators found that SBS2/SBS13 mutations were present in 17% of crypts, more frequent than most other normal tissues. [Nature Genetics] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that cell types with equivalent functional roles in the corpus and antrum shared similar transcriptional states including the poorly characterized stem cells of the isthmus region. [Nature Cell Biology] |
|
|
|
| The authors identified a circular RNA, circBtnl1, that was highly expressed in intestinal stem cells. Loss of circBtnl1 in mice enhanced intestinal stem cell self-renewal capacity and epithelial regeneration, without changes in mRNA and protein levels of its parental gene Btnl1. [EMBO Journal] |
|
|
|
| The apoptosis, function, and stemness of intestinal stem cells were analyzed using intestinal organoids from wild type and Fut2ΔISC mice incubated with lipopolysaccharide and fucose. [Redox Biology] |
|
|
|
| Investigators revealed that exosomes released from imatinib-resistant gastrointestinal stromal tumors transmitted drug resistance to imatinib-sensitive tumors. [Oncogene] |
|
|
|
| Scientists presented p73-mediated death receptor 5 induction as a potential tumor suppressive mechanism and a critical target engaged by different cyclin-dependent kinase inhibitors in potentiating therapy-induced apoptosis in colorectal cancer cells. [Oncogene] |
|
|
|
| Investigators demonstrated that ruxolitinib alleviated colitis by inhibiting nuclear factor kappa B–related inflammation and apoptosis in addition to restoring epithelial barrier function via STAT3, providing a new strategy for ulcerative colitis treatment. [Inflammatory Bowel Diseases] |
|
|
|
| Scientists explored the function of SNX10 in intestinal epithelial cells to provide a new target for the prevention and treatment of malignant transformation and the intervention mechanism of α-hederin for further development of potential novel agents targeting SNX10. [Phytomedicine] |
|
|
|
|
| In patients with deficient mismatch repair and BRAFV600E metastatic colorectal cancer, randomized Phase III trials have established the efficacy of pembrolizumab as first-line therapy and the combination of encorafenib and cetuximab as second-line or third-line therapy. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The authors summarize and analyze the latest knowledge to further elucidate the role of IL-22 in ulcerative colitis. [Biomedicine & Pharmacotherapy] |
|
|
|
|
| C4 Therapeutics, Inc. announced the first patient had been dosed in its Phase I/II clinical trial of CFT1946, an orally bioavailable mutant-selective BiDACâ„¢ degrader for the treatment of BRAF V600 mutant solid tumors. [C4 Therapeutics (Globe Newswire)] |
|
|
|
|
| February 12 – 15, 2023 Santa Fe, New Mexico, United States |
|
|
|
|
|
| Beckman Research Institute – Monrovia, California, United States |
|
|
|
| University of Oxford – England, United Kingdom |
|
|
|
| Imperial College London – London, England, United Kingdom |
|
|
|
| UT Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| European Molecular Biology Laboratory – Heidelberg, Germany |
|
|
|
|